Bellicum Pharma (BLCM) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 8, 2016 4:05 PM EDTTwo INDs cleared by FDA to begin studies of controlled CAR T and TCR product candidates
Conference call and webcast to be held Monday, August 8, 2016 at 5 p.m. Eastern
HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the second quarter of 2016 and provided an update on recent developments.
In the last six months, we have achieved important milestones... More
